Evidence map›Paper›PMID 20388878›Full record

ArticleJournal of the National Cancer Institute2010

MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer.

Gianpiero Di Leva, Pierluigi Gasparini, Claudia Piovan, Apollinaire Ngankeu, Michela Garofalo, Cristian Taccioli, Marilena V Iorio, Meng Li, Stefano Volinia, Hansjuerg Alder and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed, 2 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

194 citing papers in PubMed, 2 syntheses or guidelines pooled it, 321 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

134 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Gianpiero Di LevaDepartment of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, 460 West, 12th Ave, Columbus, OH 43210, USA.
Pierluigi Gasparini
Claudia Piovan
Apollinaire Ngankeu
Michela Garofalo
Cristian Taccioli
Marilena V Iorio
Meng Li
Stefano Volinia
Hansjuerg Alder
Tatsuya Nakamura
Gerard Nuovo
Yunlong Liu
Kenneth P Nephew
Carlo M Croce
The Ohio State University · USFondazione IRCCS Istituto Nazionale dei Tumori · ITLaboratoire d’immunologie intégrative du cancer · FR

Funding

Role of miR155 in LeukemogenesisR01CA124541 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M · 2008 to 2012
$1.8M
FHIT Gene Therapy in Cancer Prevention and TreatmentR01CA115965 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M · 2007 to 2011
$1.1M
NCI NIH HHS R01 CA115965NCI NIH HHS R01 CA124541
6 · The paper itself

Abstract

backgroundSeveral lines of evidence have suggested that estrogen receptor alpha (ERalpha)-negative breast tumors, which are highly aggressive and nonresponsive to hormonal therapy, arise from ERalpha-positive precursors through different molecular pathways. Because microRNAs (miRNAs) modulate gene expression, we hypothesized that they may have a role in ER-negative tumor formation.

methodsGene expression profiles were used to highlight the global changes induced by miRNA modulation of ERalpha protein. miRNA transfection and luciferase assays enabled us to identify new targets of miRNA 206 (miR-206) and miRNA cluster 221-222 (miR-221-222). Northern blot, luciferase assays, estradiol treatment, and chromatin immunoprecipitation were performed to identify the miR-221-222 transcription unit and the mechanism implicated in its regulation.

resultsDifferent global changes in gene expression were induced by overexpression of miR-221-222 and miR-206 in ER-positive cells. miR-221 and -222 increased proliferation of ERalpha-positive cells, whereas miR-206 had an inhibitory effect (mean absorbance units [AU]: miR-206: 500 AU, 95% confidence interval [CI]) = 480 to 520; miR-221: 850 AU, 95% CI = 810 to 873; miR-222: 879 AU, 95% CI = 850 to 893; P < .05). We identified hepatocyte growth factor receptor and forkhead box O3 as new targets of miR-206 and miR-221-222, respectively. We demonstrated that ERalpha negatively modulates miR-221 and -222 through the recruitment of transcriptional corepressor partners: nuclear receptor corepressor and silencing mediator of retinoic acid and thyroid hormone receptor.

conclusionsThese findings suggest that the negative regulatory loop involving miR-221-222 and ERalpha may confer proliferative advantage and migratory activity to breast cancer cells and promote the transition from ER-positive to ER-negative tumors.

Indexed as

Transcription, GeneticBlotting, NorthernBlotting, WesternBreast NeoplasmsCell Line, TumorCell ProliferationChromatin ImmunoprecipitationEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticGenes, erbB-2HumansMicroarray AnalysisMicroRNAsPlasmidsPolymerase Chain ReactionESR1 protein, humanEstrogen Receptor alphaMicroRNAsMIR221, humanMIR222, humanMIRN206 microRNA, humanRNA, Messenger

Identifiers

PMID20388878
PMCPMC2873185
OpenAlexW2131132514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.